The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1450
September 1, 2014
View Complete Issue         Table of Contents 2019 
Statins and Diabetes Risk
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Statins and Diabetes Risk
September 1, 2014 (Issue: 1450)
In 2012, the FDA required manufacturers of HMG-CoA reductase inhibitors (statins) to add a warning to their labels about reports of increased blood glucose and glycosylated hemoglobin (HbA1c) levels. Since then, several new studies have been...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Statins and Diabetes Risk
Article code: 1450a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.